OJEMDA™ (tovorafenib)

About Day One Biopharmaceuticals

Day One Biopharmaceuticals is a mission-driven oncology company founded to address the systemic failure of traditional drug development to deliver timely therapies for children with cancer. The company's innovative 'Search & Development' model focuses on acquiring and developing promising clinical-stage or approved targeted therapies for high-unmet-need cancers. A major milestone was achieved in 2024 with the FDA approval of OJEMDA™ for pediatric low-grade glioma, transitioning Day One into a commercial entity and proving its unique operational strategy. The company is now leveraging this success to expand its pipeline through strategic acquisitions and internal development.

Therapeutic Areas